Younger tamoxifen-treated breast cancer patients also had higher risk of endometrial cancer and the risk could be reduced by sequenced aromatase inhibitor use: A population-based study in Taiwan.

Journal: Tzu chi medical journal
Published Date: Jul 23, 2019

Abstract

OBJECTIVE: Previous Western studies reported that older (≥50 years) breast cancer survivors with tamoxifen treatment had higher risk of endometrial cancer. This study aims to disclose whether younger (<50 years) tamoxifen-treated breast cancer patients also had higher risk of endometrial cancer and to examine whether sequenced aromatase inhibitor (AI) use could reduce the risk.

Authors

  • Sung-Chao Chu
    Department of Hematology and Oncology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan.
  • Chia-Jung Hsieh
    Department of Public Health, Tzu Chi University, Hualien, Taiwan.
  • Tso-Fu Wang
    Department of Hematology and Oncology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan.
  • Mun-Kun Hong
    Institute of Medical Sciences, Tzu Chi University, Hualien, Taiwan.
  • Tang-Yuan Chu
    Institute of Medical Sciences, Tzu Chi University, Hualien, Taiwan.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals